A citation-based method for searching scientific literature

Leo Timmers, José P S Henriques, Dominique P V de Kleijn, J Hans Devries, Hans Kemperman, Paul Steendijk, Cees W J Verlaan, Marjolein Kerver, Jan J Piek, Pieter A Doevendans, Gerard Pasterkamp, Imo E Hoefer. J Am Coll Cardiol 2009
Times Cited: 345







List of co-cited articles
1109 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
Jacob Lønborg, Niels Vejlstrup, Henning Kelbæk, Hans Erik Bøtker, Won Yong Kim, Anders B Mathiasen, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Peter Clemmensen,[...]. Eur Heart J 2012
380
44


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
31

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.
Mohammad Hossein Noyan-Ashraf, M Abdul Momen, Kiwon Ban, Al-Muktafi Sadi, Yu-Qing Zhou, Ali M Riazi, Laurie L Baggio, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2009
398
26

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
26

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Kiwon Ban, M Hossein Noyan-Ashraf, Judith Hoefer, Steffen-Sebastian Bolz, Daniel J Drucker, Mansoor Husain. Circulation 2008
734
25

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.
Amal K Bose, Mihaela M Mocanu, Richard D Carr, Christian L Brand, Derek M Yellon. Diabetes 2005
453
24

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
Lazaros A Nikolaidis, Sunil Mankad, George G Sokos, Glen Miske, Ankur Shah, Dariush Elahi, Richard P Shannon. Circulation 2004
649
23

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
23


Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia.
Jacob Lønborg, Henning Kelbæk, Niels Vejlstrup, Hans Erik Bøtker, Won Yong Kim, Lene Holmvang, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Christian Juhl Terkelsen,[...]. Circ Cardiovasc Interv 2012
156
18

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
17

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts.
Tingcun Zhao, Pratik Parikh, Siva Bhashyam, Hakki Bolukoglu, Indu Poornima, You-Tang Shen, Richard P Shannon. J Pharmacol Exp Ther 2006
232
16

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy.
Lazaros A Nikolaidis, Dariush Elahi, Teresa Hentosz, Aaron Doverspike, Rhonda Huerbin, Lee Zourelias, Carol Stolarski, You-tang Shen, Richard P Shannon. Circulation 2004
389
15

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Kenneth B Margulies, Adrian F Hernandez, Margaret M Redfield, Michael M Givertz, Guilherme H Oliveira, Robert Cole, Douglas L Mann, David J Whellan, Michael S Kiernan, G Michael Felker,[...]. JAMA 2016
281
15

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
13

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
13

Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Wei Ren Chen, Shun Ying Hu, Yun Dai Chen, Ying Zhang, Geng Qian, Jing Wang, Jun Jie Yang, Zhi Feng Wang, Feng Tian, Qing Xiu Ning. Am Heart J 2015
67
19

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
829
13

Myocardial reperfusion injury.
Derek M Yellon, Derek J Hausenloy. N Engl J Med 2007
12

A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.
Mohammad Hossein Noyan-Ashraf, Eric Akihiko Shikatani, Irmgard Schuiki, Ilya Mukovozov, Jun Wu, Ren-Ke Li, Allen Volchuk, Lisa Annette Robinson, Filio Billia, Daniel J Drucker,[...]. Circulation 2013
157
12

Effect of cyclosporine on reperfusion injury in acute myocardial infarction.
Christophe Piot, Pierre Croisille, Patrick Staat, Hélène Thibault, Gilles Rioufol, Nathan Mewton, Rachid Elbelghiti, Thien Tri Cung, Eric Bonnefoy, Denis Angoulvant,[...]. N Engl J Med 2008
942
11

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
11


GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.
Minsuk Kim, Mathew J Platt, Tadao Shibasaki, Susan E Quaggin, Peter H Backx, Susumu Seino, Jeremy A Simpson, Daniel J Drucker. Nat Med 2013
300
10


Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
9

Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium.
Megan DeNicola, Jianfeng Du, Zhengke Wang, Naohiro Yano, Ling Zhang, Yigang Wang, Gangjian Qin, Shougang Zhuang, Ting C Zhao. Am J Physiol Endocrinol Metab 2014
39
23

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.
Que Liu, Christen Anderson, Anatoly Broyde, Clara Polizzi, Rayne Fernandez, Alain Baron, David G Parkes. Cardiovasc Diabetol 2010
91
9

Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment-Elevation Myocardial Infarction.
Wei Ren Chen, Yun Dai Chen, Feng Tian, Na Yang, Liu Quan Cheng, Shun Ying Hu, Jing Wang, Jun Jie Yang, Shi Feng Wang, Xiao Fang Gu. Circ Cardiovasc Imaging 2016
50
18

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
Anders Jorsal, Caroline Kistorp, Pernille Holmager, Rasmus Stilling Tougaard, Roni Nielsen, Anja Hänselmann, Brian Nilsson, Jacob Eifer Møller, Jakob Hjort, Jon Rasmussen,[...]. Eur J Heart Fail 2017
193
9

Cardiovascular actions of incretin-based therapies.
John R Ussher, Daniel J Drucker. Circ Res 2014
236
8

Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model.
Jens Kristensen, Ulrik M Mortensen, Morten Schmidt, Peter Haubjerg Nielsen, Torsten Toftegaard Nielsen, Michael Maeng. BMC Cardiovasc Disord 2009
57
14

Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning.
Zhi-Qing Zhao, Joel S Corvera, Michael E Halkos, Faraz Kerendi, Ning-Ping Wang, Robert A Guyton, Jakob Vinten-Johansen. Am J Physiol Heart Circ Physiol 2003
8

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
8

Postconditioning the human heart.
Patrick Staat, Gilles Rioufol, Christophe Piot, Yves Cottin, Thien Tri Cung, Isabelle L'Huillier, Jean-François Aupetit, Eric Bonnefoy, Gérard Finet, Xavier André-Fouët,[...]. Circulation 2005
776
8


Combination therapy with remote ischaemic conditioning and insulin or exenatide enhances infarct size limitation in pigs.
Juan José Alburquerque-Béjar, Ignasi Barba, Javier Inserte, Elisabet Miró-Casas, Marisol Ruiz-Meana, Marcos Poncelas, Úrsula Vilardosa, Laura Valls-Lacalle, Antonio Rodríguez-Sinovas, David Garcia-Dorado. Cardiovasc Res 2015
37
21


Cardioprotective effects of exenatide against oxidative stress-induced injury.
Guanglei Chang, Dongying Zhang, Hui Yu, Peng Zhang, Ying Wang, Aihua Zheng, Shu Qin. Int J Mol Med 2013
53
15

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy.
Lazaros A Nikolaidis, Dariush Elahi, You-Tang Shen, Richard P Shannon. Am J Physiol Heart Circ Physiol 2005
207
8


GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
Charles Pyke, R Scott Heller, Rikke K Kirk, Cathrine Ørskov, Steffen Reedtz-Runge, Peter Kaastrup, Anders Hvelplund, Linda Bardram, Dan Calatayud, Lotte Bjerre Knudsen. Endocrinology 2014
401
8

Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix.
Emma Robinson, Roslyn S Cassidy, Mitchel Tate, Youyou Zhao, Samuel Lockhart, Danielle Calderwood, Rachel Church, Mary K McGahon, Derek P Brazil, Barbara J McDermott,[...]. Basic Res Cardiol 2015
42
19

Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection.
John R Ussher, Laurie L Baggio, Jonathan E Campbell, Erin E Mulvihill, Minsuk Kim, M Golam Kabir, Xiemin Cao, Benjamin M Baranek, Doris A Stoffers, Randy J Seeley,[...]. Mol Metab 2014
79
10

Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: the EXAMI study.
Flip J P Bernink, Leo Timmers, Michaela Diamant, Martijn Scholte, Aernout M Beek, Otto Kamp, Koen M J Marques, Robert N Denham, Weena J Y Chen, Pieter A Doevendans,[...]. Int J Cardiol 2013
32
25

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Michael A Nauck, Juris J Meier, Matthew A Cavender, Mirna Abd El Aziz, Daniel J Drucker. Circulation 2017
233
8

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.
George G Sokos, Lazaros A Nikolaidis, Sunil Mankad, Dariush Elahi, Richard P Shannon. J Card Fail 2006
476
7

Cardiovascular biology of the incretin system.
John R Ussher, Daniel J Drucker. Endocr Rev 2012
365
7



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.